- Hahnova Cygalova L., Hofman J., Ceckova M., Staud F.: Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL Prazosin: Effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 2009; 331 (3): 1118 – 25 (IF for 2009 = 4.309)
- Piterkova J., Hofman J., Mieslerova B., Sedlarova M., Luhova L., Lebeda A., Petřivalský M.: Dual role of nitric oxide in Solanum spp.-Oidium neolycopersici interactions. Environ Exp Bot 2011; 74: 37 – 44 (IF for 2011 = 2.985)
- Hofman J., Ahmadimoghaddam D., Hahnova L., Pavek P., Ceckova M., Staud F.: Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res 2012; 65 (3): 312 – 9 (IF for 2012 = 4.346)
- Ahmadimoghaddam D., Hofman J., Zemankova L., Nachtigal P., Dolezelova E., Cerveny L., Ceckova M., Micuda S., Staud F.: Synchronized activity of organic cation transporter 3 (Oct3/SLC22A3) and multidrug and toxin extrusion 1 (Mate 1/SLC47A1) transporter in transplacental passage of MPP+ in rat. Toxicol Sci 2012; 128 (2): 471 – 81 (IF for 2012 = 4.328)
- Piterkova J., Luhova L., Hofman J., Tureckova V., Novak O., Petrivalsky M., Fellner M.: Nitric oxide is involved in light-specific responses of tomato during germination under normal and osmotic stress conditions. Ann Bot 2012; 110 (4): 767 - 76 (IF for 2012 = 3.449)
- Hofman J., Buncek M., Haluza R., Streinz L., Ledvina M., Cigler P.: In vitro transfection mediated by dendrigraft poly(L-lysines): effect of structure and molecule size. Macromol Biosci 2013; 13 (2): 167 – 76 (IF for 2013 = 3.650)
- Hofman J., Kučera R., Cihalova D., Klimes J., Ceckova M., Staud F.: Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-glycoprotein (ABCB1). PLoS One 2013; 8 (10): e75520 (IF for 2013 = 3.534)
- Cihalova D., Hofman J., Ceckova M., Staud F.: Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PLoS One 2013; 8 (12): e83467 (IF for 2013 = 3.534)
- Hofman J., Malcekova B., Skarka A., Novotna E., Wsol V.: Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol 2014; 278 (3): 238 - 48 (IF for 2014 = 3.705)
- Skarydova L., Hofman J., Chlebek J., Havrankova J., Kosanova K., Skarka A., Hostalkova A., Plucha T., Cahlikova L., Wsol V.: Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. J Steroid Biochem Mol Biol 2014; 143: 250 – 8 (IF for 2014 = 3.628)
-
Hofman J., Skarka A., Havrankova J., Wsol V.: Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochem Pharmacol 2015; 96 (3): 168 - 78 (IF for 2015 = 5.091)
-
Hofman J., Kučera R., Neumanova Z., Klimes J., Ceckova M., Staud F.: Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Xenobiotica 2016; 46(5): 416-23 (IF for 2016 = 1.932).
-
Zemanova L., Hofman J., Novotna E., Musilek K., Lundova T., Havrankova J., Hostalkova A., Chlebek J., Cahlikova L., Wsol V.: Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment. J Nat Prod 2015; 78 (11): 2666 - 74 (IF for 2015 = 3.662)
-
Hintzpeter J., Seliger J.M., Hofman J., Martin H.J., Wsol V., Maser E.: Inhibition of human anthracycline reductases by emodin - a possible remedy for anthracycline resistance. Toxicol Appl Pharmacol 2016; 293: 21-9 (IF for 2016 = 3.791)
-
Siroka J., Ceckova M., Urbanek L., Krystof V., Gucky T., Hofman J., Strnad M., Staud F.: LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1089: 24-32 (IF for 2018 = 2.813)
-
Sorf A., Hofman J, Kucera R., Staud F., Ceckova M.: Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochem Pharmacol 2018; 154: 10-7 (IF for 2018 = 4.825)
-
Novotna E., Büküm N., Hofman J., Flaxova M., Kouklikova E., Louvarova D., Wsol V.: Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Arch Toxicol 2018; 92: 2845-2857 (IF for 2018 = 5.741)
-
Novotna E., Büküm N., Hofman J., Flaxova M., Kouklikova E., Louvarova D., Wsol V.: Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3). Biochem Pharmacol 2018; 156: 22-31 (IF for 2018 = 4.825)
-
Büküm N., Novotna E., Morell A., Hofman J., Wsol V.: Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. Chem Biol Interact 2019; 302: 101-7 (IF for 2019 = 3.723)
-
Sorf A., Novotna E., Hofman J., Morell A., Staud F., Wsol V., Ceckova M.: Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochem Pharmacol 2019; 163: 290-8 (IF for 2019 = 4.960)
- Hofman J., Sorf A., Vagiannis D., Sucha S., Novotna E., Kammerer S., Küpper J-H., Ceckova M., Staud F.: Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metab Dispos 2019; 47(7): 699-709 (IF for 2019 = 3.231)
- Hofman J., Sorf A., Vagiannis D., Sucha S., Kammerer S., Küpper J-H., Chen S., Guo L., Ceckova M., Staud F.: Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Mol Pharmaceut 2019; 16(11): 4436-4450 (IF for 2019 = 4.321)
- Vagiannis D., Novotna E., Skarka A., Kammerer S., Küpper J-H., Chen S., Guo L., Staud F., Hofman J.: Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers 2020; 12(4): E813 (IF for 2020 = 6.639)
- Vagiannis D., Zhang Y., Novotna E., Morell A., Hofman J.: Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. Biochem Pharmacol 2020; 178: 114061 (IF for 2020 = 5.858)
- Novotna E., Morell A., Büküm N., Hofman J., Danielisová P., Wsól V.: Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?. Arch Toxicol 2020; 94: 3059-3068 (IF for 2020 = 5.153)
- Tavares T., Hofman J., Lekešová A., Zelazkova J., Wsol V.: Olaparib synergizes the anticancer activity of daunorubicin via interaction with AKR1C3. Cancers 2020; 12(11):3127 (IF for 2020 = 6.639)
- Hofman J., Vagiannis D., Chen S., Guo L.: Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact 2021; 340:109448 (IF for 2021 = 5.168)
- Vagiannis D., Budagaga Y., Morell A., Zhang Y., Novotná E., Skarka A., Kammerer S., Küpper J-H., Hanke I., Rozkoš T., Hofman J.: Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo. Int J Mol Sci 2021; 22(21):11936 (IF for 2021 = 6.208)
- Sorf A., Vagiannis D., Fahda A., Hofman J., Ceckova M.: Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol 2022; 434:115797 (IF for 2022/2023 = 3.8)
- Vagiannis D., Zhang Y., Budagaga Y., Novotna E., Skarka A., Kammerer S., Küpper J-H., Hofman J.: Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol 2022; 434:115823 (IF for 2022/2023 = 3.8)
- Zhang Y., Vagiannis D., Budagaga Y., Sabet Z., Hanke I., Rozkoš T., Hofman J.: Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo. Biochem Pharmacol 2022; 199:115009 (IF for 2022/2023 = 5.8)
- Morell A., Budagaga Y., Vagiannis D., Zhang Y., Laštovičková L., Novotná E., Haddad A., Haddad M., Portillo R., Hofman J., Wsól V.: Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. Arch Toxicol 2022; 96(12): 3265-3277 (IF for 2022/2023 = 6.1)
- Čermáková L., Hofman J., Laštovičková L., Havlíčková L., Špringrová I., Novotná E., Wsól V: Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. Pharmaceutics 2022; 14(10): 1994 (IF for 2022/2023 = 5.4)
-
Sabet Z., Vagiannis D., Budagaga Y., Zhang Y., Novotná E., Hanke I., Rozkoš T., Hofman J.: Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study. Int J Mol Sci 2022; 23(22): 14338 (IF for 2022/2023 = 5.6)
-
Zhang Y., Vagiannis D., Budagaga Y., Sabet Z., Hanke I., Rozkoš T., Hofman J.: Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. Pharmaceutics 2022; 14(12): 2595 (IF for 2022/2023 = 5.4)
-
Budagaga Y., Sabet Z., Zhang Y., Novotná E., Hanke I., Rozkoš T., Hofman J.: Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo. Biochem Pharmacol 2023;216:115769 (IF for 2022/2023 = 5.8)